Hemab Therapeutics (NASDAQ:COAG – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($23.98) earnings per share for the quarter, Zacks reports.
Hemab Therapeutics Price Performance
NASDAQ COAG traded up $0.51 during trading hours on Thursday, reaching $26.98. The company’s stock had a trading volume of 7,828 shares, compared to its average volume of 238,223. Hemab Therapeutics has a 1 year low of $23.00 and a 1 year high of $36.61.
Insider Transactions at Hemab Therapeutics
In related news, major shareholder Ra Capital Management, L.P. acquired 6,387 shares of Hemab Therapeutics stock in a transaction dated Tuesday, May 12th. The shares were purchased at an average price of $24.90 per share, for a total transaction of $159,036.30. Following the completion of the transaction, the insider directly owned 6,372,170 shares in the company, valued at approximately $158,667,033. This represents a 0.10% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have purchased 2,898,074 shares of company stock worth $53,650,008.
Analysts Set New Price Targets
Read Our Latest Report on Hemab Therapeutics
Hemab Therapeutics Company Profile
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Featured Stories
- Five stocks we like better than Hemab Therapeutics
- Target Shows Strengths, But Analysts Want to See More
- NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating
- Corpay’s Quiet Strength Is Winning Wall Street
- Investors Abandoned These 3 AI Stocks Too Early, Says Jeff Clark
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
